tasquinimod (ABR-215050) / Active Biotech, Ipsen 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tasquinimod (ABR-215050) / Active Biotech, Ipsen
ACTRN12621000016831p: Effect of Tasquinimod on COVID-19 patients

Not yet recruiting
2
125
 
Hunter medical research institute, Hunter medical research institute
COVID-19
 
 
NCT06327100: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Not yet recruiting
2
33
US
Ruxolitinib, Jakafi, INCB018424, INC424, Tasquinimod
M.D. Anderson Cancer Center, Active Biotech AB
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
05/29
05/31
NCT04405167: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Recruiting
1
34
US
Tasquinimod, IRd chemotherapy, Ixazomib, Lenalidomide, Dexamethasone
University of Pennsylvania, Active Biotech AB
Multiple Myeloma
07/24
07/25

Download Options